Next generation diagnostics and oral treatment for visceral leishmaniasis in Eastern Africa: transforming patient care through innovation

Project Details


Left untreated, visceral leishmaniasis (VL) is fatal. Current diagnostics are invasive or have low sensitivity, and
treatments are neither completely effective nor adapted for use in the remote VL endemic areas. Early
diagnosis and effective prompt treatment reduce the prevalence of VL and prevents disabilities and death, as
well as reduce transmission of this poverty related disease.
The VL-INNO consortium proposes innovative approaches for the development of new oral safe drugs and
antigen detection rapid diagnostics test, with objective of delivering a test and treat package that can be
deployed in low-resource settings, closer to the communities affected by the disease, offering a paradigm shift
in combating visceral leishmaniasis. This is possible due to the well-established collaborations between the
partners, as well as extensive experience in this disease environment and health care settings.
The proposal aims to implement a proof of concept study for the development of a new, orally efficacious
treatment regimen for VL together with a new antigen based rapid diagnostic testing, low-invasive
biomarkers and test-of-cure assays and the use of digital technologies and artificial intelligence to
improve parasitological diagnosis and quality control.
Effective start/end date1/10/2131/12/24


  • European & Developing Countries Clinical Trials Partnership : €388,124.11